Enanta Pharma (ENTA) Misses Q2 EPS by 11c

Enanta Pharma (NASDAQ: ENTA) reported Q2 EPS of ($1.09), $0.11 worse than the analyst estimate of ($0.98). Revenue for the quarter came in at $20.1 million versus the consensus estimate of $24.38 million.

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• FactSet Research Systems (FDS) PT Raised to $253 at Jefferies
• SAS CEO van der Werff emerges as frontrunner for Air Canada top job - Bloomberg